These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 27416043)

  • 1. Importance of the Evaluation of N-Acetyltransferase Enzyme Activity Prior to 5-Aminosalicylic Acid Medication for Ulcerative Colitis.
    Matthis AL; Zhang B; Denson LA; Yacyshyn BR; Aihara E; Montrose MH
    Inflamm Bowel Dis; 2016 Aug; 22(8):1793-802. PubMed ID: 27416043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute murine colitis reduces colonic 5-aminosalicylic acid metabolism by regulation of N-acetyltransferase-2.
    Ramírez-Alcántara V; Montrose MH
    Am J Physiol Gastrointest Liver Physiol; 2014 Jun; 306(11):G1002-10. PubMed ID: 24742986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Addition of Berberine to 5-Aminosalicylic Acid for Treatment of Dextran Sulfate Sodium-Induced Chronic Colitis in C57BL/6 Mice.
    Li YH; Zhang M; Xiao HT; Fu HB; Ho A; Lin CY; Huang Y; Lin G; Bian ZX
    PLoS One; 2015; 10(12):e0144101. PubMed ID: 26642326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis.
    Olaisen M; Spigset O; Flatberg A; Granlund AVB; Brede WR; Albrektsen G; Røyset ES; Gilde B; Sandvik AK; Martinsen TC; Fossmark R
    Aliment Pharmacol Ther; 2019 May; 49(10):1301-1313. PubMed ID: 30895635
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine.
    Naganuma M; Iwao Y; Ogata H; Inoue N; Funakoshi S; Yamamoto S; Nakamura Y; Ishii H; Hibi T
    Inflamm Bowel Dis; 2001 Aug; 7(3):221-5. PubMed ID: 11515848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms.
    Stocco G; Cuzzoni E; De Iudicibus S; Favretto D; Malusà N; Martelossi S; Pozzi E; Lionetti P; Ventura A; Decorti G
    World J Gastroenterol; 2015 Mar; 21(12):3571-8. PubMed ID: 25834322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of OATP2B1 by proinflammatory cytokines leads to 5-ASA hyposensitivity in Ulcerative colitis.
    Li P; Luo J; Jiang Y; Pan X; Dong M; Chen B; Wang J; Zhou H; Jiang H; Duan Y; Lin N
    Chem Biol Interact; 2024 Aug; 398():111074. PubMed ID: 38844255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats.
    Tozaki H; Odoriba T; Okada N; Fujita T; Terabe A; Suzuki T; Okabe S; Muranishi S; Yamamoto A
    J Control Release; 2002 Jul; 82(1):51-61. PubMed ID: 12106976
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal concentrations of N-acetyl-5-aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine.
    Fukuda T; Naganuma M; Takabayashi K; Hagihara Y; Tanemoto S; Nomura E; Yoshimatsu Y; Sugimoto S; Nanki K; Mizuno S; Mikami Y; Fukuhara K; Sujino T; Mutaguchi M; Inoue N; Ogata H; Iwao Y; Abe T; Kanai T
    J Gastroenterol Hepatol; 2020 Nov; 35(11):1878-1885. PubMed ID: 32250471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of Pharmaceutical Formulation on the Mucosal Concentration of 5-Aminosalicylic Acid and N-Acetylmesalamine in Japanese Patients with Ulcerative Colitis.
    Yamamoto Y; Masuda S; Nakase H; Matsuura M; Maruyama S; Hisamatsu T; Suzuki Y; Matsubara K
    Biol Pharm Bull; 2019 Jan; 42(1):81-86. PubMed ID: 30369547
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Jianpi Qingchang decoction alleviates ulcerative colitis by inhibiting nuclear factor-κB activation.
    Zheng L; Zhang YL; Dai YC; Chen X; Chen DL; Dai YT; Tang ZP
    World J Gastroenterol; 2017 Feb; 23(7):1180-1188. PubMed ID: 28275298
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous Treatment of 5-Aminosalicylic Acid and Treadmill Exercise More Effectively Improves Ulcerative Colitis in Mice.
    Jin JJ; Ko IG; Hwang L; Kim SH; Jee YS; Jeon H; Park SB; Jeon JW
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791116
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased expression of lipocalin-type-prostaglandin D synthase in ulcerative colitis and exacerbating role in murine colitis.
    Hokari R; Kurihara C; Nagata N; Aritake K; Okada Y; Watanabe C; Komoto S; Nakamura M; Kawaguchi A; Nagao S; Urade Y; Miura S
    Am J Physiol Gastrointest Liver Physiol; 2011 Mar; 300(3):G401-8. PubMed ID: 21163901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis.
    Ricart E; Taylor WR; Loftus EV; O'Kane D; Weinshilboum RM; Tremaine WJ; Harmsen WS; Zinsmeister AR; Sandborn WJ
    Am J Gastroenterol; 2002 Jul; 97(7):1763-8. PubMed ID: 12135032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determination of the active moiety of BX661A, a new therapeutic agent for ulcerative colitis, by studying its therapeutic effects on ulcerative colitis induced by dextran sulfate sodium in rats.
    Kimura I; Kawasaki M; Nagahama S; Matsuda A; Kataoka M; Kokuba Y
    Arzneimittelforschung; 1998 Nov; 48(11):1091-6. PubMed ID: 9850431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-Aminosalicylic acid, a specific drug for ulcerative colitis.
    Hauso Ø; Martinsen TC; Waldum H
    Scand J Gastroenterol; 2015 Aug; 50(8):933-41. PubMed ID: 25733192
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis.
    Frieri G; Giacomelli R; Pimpo M; Palumbo G; Passacantando A; Pantaleoni G; Caprilli R
    Gut; 2000 Sep; 47(3):410-4. PubMed ID: 10940280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of drugs on colonic eicosanoid accumulation in active ulcerative colitis.
    Eliakim R; Karmeli F; Chorev M; Okon E; Rachmilewitz D
    Scand J Gastroenterol; 1992 Nov; 27(11):968-72. PubMed ID: 1455196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eudragit S100 coated iron oxide-chitosan nanocomposites for colon targeting of 5-aminosalicylic acid ameliorate ulcerative colitis by improving intestinal barrier function and inhibiting NLRP3 inflammasome.
    Zhang D; Wan H; Zhao R; Zhang Y; Chen H
    Int Immunopharmacol; 2024 Sep; 139():112661. PubMed ID: 39008936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NAT1 genotypes do not predict response to mesalamine in patients with ulcerative colitis.
    Hausmann M; Paul G; Menzel K; Brunner-Ploss R; Falk W; Schölmerich J; Herfarth H; Rogler G
    Z Gastroenterol; 2008 Mar; 46(3):259-65. PubMed ID: 18322880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.